| ||
| Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent ... PharmiWeb.com (press release) Afatinib is also being investigated for non-small cell lung cancer (NSCLC) in phase III clinical trials, the most common type of cancer5. ... See all stories on this topic » | ||
| Fitch Rates Amgen's Senior Notes 'A' Trading Markets (press release) The late-stage pipeline includes motesanib diphosphate, a treatment for non-small cell lung cancer; and key line-extensions for denosumab, the bone loss ... See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment